CSF Tau supplements 14-3-3 protein detection for sporadic Creutzfeldt–Jakob disease diagnosis while transitioning to next generation diagnostics. (April 2018)

• Record Type: Journal Article
• Authors: Li, Qiao-Xin; Varghese, Shiji; Sarros, Shannon; Stehmann, Christiane; Doecke, James D.; Fowler, Christopher J.; Masters, Colin L.; Collins, Steven J.
• Is Part Of: Journal of clinical neuroscience. Volume 50(2018)
• Page Start: 292
• Page End: 293
• Publication Date: 2018-04
• Subjects: CJD -- Tau -- 14-3-3 -- CSF; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2018.01.064
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: Pre-mortem diagnosis of sporadic CJD is aided by CSF biomarkers. CSF 14-3-3 and Tau levels are useful while adopting RT-QuIC protein amplification. For CJD diagnosis CSF Tau levels usefully supplement 14-3-3 protein detection. Abstract: The pre-mortem clinical diagnosis of Creutzfeldt–Jakob disease (CJD) is supported by biomarkers, especially cerebrospinal fluid (CSF) 14-3-3 and total tau (Tau) protein levels. These CSF biomarkers have proven the most useful prior to transitioning to powerful next generation diagnostics employing protein amplification techniques such as the real time quaking-induced conversion (RT-QuIC) assay. To enhance national diagnostic capacity while transitioning to RT-QuIC assays an optimized CSF Tau cutoff was determined and shown to usefully supplement 14-3-3 protein detection.